Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acorda Buys Its Way Into A Parkinson's Franchise

This article was originally published in The Pink Sheet Daily

Executive Summary

Having acquired Parkinson's candidate CVT-301 in the 2014 purchase of Civitas, Acorda sees Biotie's Phase III tozadenant as an ideal candidate to create a complementary Parkinson's disease franchise.

You may also be interested in...



Sunovion Adds Parkinson's To CNS Franchise With Cynapsus Buyout

Sumitomo Dainippon unit pays a 123% premium to acquire Cynapsus and its Phase III Parkinson's drug APL-130277, with at least one analyst speculating it paid a high price in order to avoid a bidding war.

Merck Halts Preladenant Development In Parkinson’s Following Phase III Failures

Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.

Not Too Late? German Industry Presses For EU MRA With Post-Brexit UK

BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December. 

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel